High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1284-1287

  Xu, Jialin ^a   Zhou, Yuhong ^a   Zhang, Jing ^b   Chen, Yuancheng ^b   Zhuang, Rongyuan ^a   Liu, Tianshu ^a   Cai, Weimin ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Adverse drug reaction; Cancer; Cytidine deaminase; Gemcitabine; Pharmacogenetics; Polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTIDINE DEAMINASE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CDA GENE; CHINESE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; EYE SWELLING; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INCIDENCE; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; NEUTROPENIA; POLYMORPHISM, GENETIC;

EID: 84861330349     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.018     Document Type: Article

References (28)

1. Ciccolini J., Mercier C., Dahan L., et al. Integrating pharmacogenetics into gemcitabine dosing-time for a change?. Nat Rev Clin Oncol 2011, 8:439-444.
2. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18:122-130.
3. Mazzanti P., Massacesi C., Rocchi M.B.L., et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003, 41:81-89.
4. Zatloukal P., Petruzelka L., Zemanova M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41:321-331.
5. Wong A., Soo R.A., Yong W.P., Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009, 41:77-88.
6. Ciccolini J., Dahan L., Andre N., et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010, 28:160-165.
7. Yue L., Saikawa Y., Ota K., et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003, 13:29-38.
8. Sugiyama E., Kaniwa N., Kim S.R., et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminse polymorphism. J Clin Oncol 2007, 25:32-42.
9. Sugiyama E., Kaniwa N., Kim S.R., et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients. Clin Pharmacokinet 2010, 49:549-558.
10. Gilbert J.A., Salavaggione O.E., Ji Y., et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006, 12:1794-1803.
11. Tibaldi C., Giovannetti E., Vasile E., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
12. Soo R.A., Wang L.Z., Ng S.S., et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009, 63:121-128.
13. Carpi F.M., Xu J., Vincenzetti S., et al. Rapid allele-specific PCR method for CDA 79 A>C (K27Q) genotyping: a useful pharmacogenetic tool and world-wide polymorphism distribution. Clin Chim Acta 2011, 412:2237-2240.
14. Carpi F.M., Vincenzetti S., Micozzi D., et al. PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population. Mol Biol Rep 2010, 37:3363-3368.
15. *3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009, 100:870-873.
16. Yonemori K., Ueno H., Okusaka T., et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005, 11:2620-2624.
17. Yue L.J., Chen X.W., Li C.R., et al. Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007, 24:699-702. [Article in Chinese].
18. Sugiyama E., Lee S.J., Lee S.S., et al. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet 2009, 24:553-556.
19. Mercier C., Dupuis C., Blesius A., et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 2009, 63:1177-1180.
20. Farrell J.J., Bae K., Wong J., et al. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 2011, 10.1038/tpj.2011.22.
21. Tanaka M., Javle M., Dong X., et al. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010, 116:5325-5335.
22. Ganti A., Parr A., Nguyen D., Grem J. Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. J Clin Oncol 2007, 24. [Meeting Abstracts].
23. Mercier C., Raynal C., Dahan L., et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007, 17:841-844.
24. Giovannetti E., Laan A.C., Vasile E., et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008, 27:720-725.
25. Toffalorio F., Giovannetti E., De Pas T., et al. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. Pharmacogenomics J 2010, 10:180-190.
26. Metharom E., Galettis P., Manners S., et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol 2011, 7:65-74.
27. Joerger M., Burgers J.A., Baas P., et al. Gene Polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2012, 69:25-33.
28. Maring J.G., Wachters F.M., Slijfer M., et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010, 66:611-617.